公开(公告)号：US10076542B2

公开(公告)日：2018-09-18

申请号：US15914746

申请日：2018-03-07

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Samuel Strober ,  Robert Lowsky

IPC分类号： C12N5/00 ,  C12N5/02 ,  A61K38/00 ,  A61K35/12 ,  A61N5/10 ,  A61K35/17 ,  A61K39/395 ,  A61K35/22 ,  A61K35/28

CPC分类号： A61K35/12 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K35/14 ,  A61K35/17 ,  A61K35/22 ,  A61K35/28 ,  A61K38/13 ,  A61K38/193 ,  A61K39/001 ,  A61K39/395 ,  A61K39/39541 ,  A61K41/00 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/54 ,  A61K2039/57 ,  A61N5/10 ,  A61K2300/00

摘要： Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

公开(公告)号：US20180256712A1

公开(公告)日：2018-09-13

申请号：US15972972

申请日：2018-05-07

申请人： The Trustees of the University of Pennsylvania ,  The Children's Hospital of Philadelphia

发明人： Carl H. June ,  Bruce L. Levine ,  Michael D. Kalos ,  Stephan Grupp

IPC分类号： A61K39/395 ,  A61K31/713 ,  A61K35/00 ,  A61K45/06 ,  C12Q1/6886 ,  G01N33/68 ,  A61K31/7088 ,  A61K48/00 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K31/7088 ,  A61K31/713 ,  A61K35/00 ,  A61K45/06 ,  A61K48/0083 ,  A61K2039/505 ,  A61K2039/515 ,  C12Q1/6886 ,  G01N33/6803 ,  G01N2333/52 ,  G01N2800/52 ,  A61K2300/00

摘要： The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.

公开(公告)号：US20180243386A1

公开(公告)日：2018-08-30

申请号：US15903214

申请日：2018-02-23

申请人： FRED HUTCHINSON CANCER RESEARCH CENTER

发明人： Cameron J. Turtle ,  Stanley R. Riddell

IPC分类号： A61K39/00 ,  C12N5/0783 ,  A61K35/17 ,  G01N33/50

CPC分类号： A61K39/00 ,  A61K35/17 ,  A61K2039/515 ,  A61K2039/57 ,  A61K2039/572 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/599 ,  G01N33/505 ,  G01N2333/54 ,  G01N2333/70557

摘要： This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18Rα and the capacity to rapidly efflux the fluorescent dye Rh123.

公开(公告)号：US20180187155A1

公开(公告)日：2018-07-05

申请号：US15905445

申请日：2018-02-26

申请人： RUBIUS THERAPEUTICS, INC.

发明人： Avak Kahvejian ,  Jordi Mata-Fink ,  Robert J. Deans ,  Tiffany F. Chen ,  John Round ,  Noubar B. Afeyan ,  Torben Straight Nissen ,  Nathan Dowden ,  Tom Wickham

IPC分类号： C12N5/078 ,  C07K14/705 ,  A61K35/18 ,  A61P17/00

CPC分类号： A61K35/18 ,  A61K35/12 ,  A61K38/191 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/515 ,  A61P17/00 ,  C07K14/705 ,  C07K2319/00 ,  C12N5/0641 ,  C12N2510/00

摘要： The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease.

公开(公告)号：US20180171298A1

公开(公告)日：2018-06-21

申请号：US15578946

申请日：2016-06-30

申请人： Cellectis

发明人： Philippe DUCHATEAU ,  Jean-Pierre CABANIOLS ,  Julien VALTON

IPC分类号： C12N5/0783 ,  C12N15/63 ,  A61K35/17 ,  A61K45/06 ,  C12N9/22 ,  C07K14/47 ,  C07K14/725 ,  C12N9/12

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K45/06 ,  A61K2039/515 ,  A61K2039/572 ,  C07K14/4703 ,  C07K14/7051 ,  C12N9/12 ,  C12N9/22 ,  C12N15/63 ,  C12N2510/00

摘要： The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.

公开(公告)号：US09977021B2

公开(公告)日：2018-05-22

申请号：US14666772

申请日：2015-03-24

申请人： The Regents of the University of California

发明人： Jeffrey A. Bluestone ,  Weihong Liu ,  Amy Putnam

IPC分类号： G01N33/53 ,  G01N33/569 ,  A61K39/00 ,  C12N5/0783 ,  G01N33/50 ,  A61K35/17 ,  A61K35/12

CPC分类号： G01N33/56972 ,  A61K35/17 ,  A61K39/0008 ,  A61K2035/122 ,  A61K2039/515 ,  C12N5/0636 ,  G01N33/505 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70596 ,  G01N2333/7155

摘要： The invention provides methods of isolating CD127lo/− immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

公开(公告)号：US20180104277A1

公开(公告)日：2018-04-19

申请号：US15567376

申请日：2016-04-21

申请人： ENLIVEX THERAPEUTICS LTD.

发明人： Dror MEVORACH ,  Shai NOVIK

IPC分类号： A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  C12N5/078 ,  A61K9/00 ,  A61P37/00

CPC分类号： A61K35/15 ,  A61K9/0019 ,  A61K35/17 ,  A61K39/0008 ,  A61K2035/122 ,  A61K2039/515 ,  A61K2039/58 ,  A61P37/00 ,  C12N5/0634 ,  C12N2501/39

摘要： Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.

公开(公告)号：US20180028639A1

公开(公告)日：2018-02-01

申请号：US15611717

申请日：2017-06-01

申请人： David S. Terman ,  David Bradley

发明人： David S. Terman ,  David Bradley

IPC分类号： A61K39/085

CPC分类号： A61K39/085 ,  A61K2039/515 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/585 ,  A61K2039/6006

摘要： Here we show that SEG/SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG/SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p

公开(公告)号：US09861689B2

公开(公告)日：2018-01-09

申请号：US15332375

申请日：2016-10-24

申请人： MaxiVAX SA

发明人： Nicolas Mach

IPC分类号： A61K39/00 ,  A61K9/00 ,  C12P21/00 ,  A61K9/48

CPC分类号： A61K39/0011 ,  A61K9/0019 ,  A61K9/4891 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/54 ,  A61K2039/55522 ,  A61K2039/6093 ,  A61M5/178 ,  A61M2202/30 ,  C12N5/0693 ,  C12P21/005 ,  Y02A50/412

摘要： Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-CSF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.

公开(公告)号：US09844586B2

公开(公告)日：2017-12-19

申请号：US12545518

申请日：2009-08-21

申请人： Petr Genrievich Lokhov

发明人： Petr Genrievich Lokhov

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/071 ,  C12N5/09

CPC分类号： A61K39/0011 ,  A61K2039/515

摘要： Accordingly to the method of the preparing of the tumor vaccine with the use of endothelial cells, live endothelial cells are treated with a protease at mild (non-deadly for cells) conditions, the splitted surface antigens are collected, the treatment of live endothelial cells is repeated after intervals which are necessary for the recovery of the surface antigens by the cells, surface antigens are accumulated until their necessary quantity is reached, the quality of the vaccine is controlled thereafter. The technical result obtained with the use of this invention consists in the enhancement of the efficiency of oncological disease treatment due to the damage of the tumor vessels caused by overcoming of the immune tolerance of organism to the endothelial cells (EC) of tumor vessels. Here one means the overcoming of immune tolerance namely to activated EC, which allows to damage mainly to the tumor vessels by the immune system.